GenScript Biotech announced plans to spin off Probio Technology as a separate Hong Kong-listed entity, triggering a 4% decline in early trading as investors parsed the capital allocation signal. The parent trades at approximately HKD 12.80 following the announcement, down from HKD 13.33 at Friday's close. GenScript acquired Probio in 2019 for USD 242 million to diversify beyond its core gene synthesis and biologics services business.
The spin-off follows eighteen months of margin pressure across GenScript's core contract research and manufacturing segments. Revenue growth in synthetic biology services decelerated to 8.2% year-over-year in the most recent quarter, down from 22.4% the prior year, as Western pharmaceutical clients reduced early-stage research budgets. Probio generates approximately USD 85 million in annual revenue from industrial enzyme and probiotic strain development, primarily serving Chinese consumer health brands and food manufacturers. The unit operates independently with separate facilities in Nanjing and carries no shared manufacturing dependencies with GenScript's Jiangsu bioprocessing campus.
The timing reflects two realities. First, GenScript's biologics contract manufacturing division faces intensifying competition from WuXi Biologics and Samsung Biologics, both of which expanded China capacity by more than 30% in the past year. Second, Chinese consumer health companies are paying higher multiples for probiotic technology than biotech services businesses command in Hong Kong. Comparable transactions include BY-HEALTH's USD 1.1 billion acquisition of Life-Space Group in 2022 and INFINITUS's minority investment in BIOHM Health at a reported 18x forward revenue. Probio's separation allows GenScript to crystallize value that the consolidated entity's 9.2x forward EBITDA multiple does not capture.
Allocators should watch for the prospectus filing within 90 days, which will detail Probio's customer concentration and margin profile. GenScript has not disclosed whether it will retain a controlling stake or distribute shares pro-rata to existing holders. The parent company's remaining business trades at approximately USD 1.8 billion market capitalization with USD 620 million in trailing revenue, implying Probio could command USD 300-400 million as a standalone if industrial biotech valuations hold. Separately, GenScript's management will likely address capacity utilization rates at its Legend Biotech partnership when it reports Q1 results in May.
The share price move suggests institutional holders view the spin-off as defensive rather than opportunistic. GenScript's ADR volume on Nasdaq spiked to 2.1 million shares in the first hour of Hong Kong trading, more than double the daily average, indicating cross-listed arbitrage and early position adjustments. The company has not announced a timetable for the Probio listing, but Hong Kong IPO processing typically requires four to six months from announcement to trading debut.